These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 17136357

  • 1. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
    Jorge R, Costa RA, Calucci D, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):1045-8. PubMed ID: 17136357
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
    Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S.
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1825-9. PubMed ID: 17345090
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
    Kovach JL, Rosenfeld PJ.
    Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.
    Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM.
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1597-602. PubMed ID: 17437123
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis.
    Potter MJ, Szabo SM, Chan EY, Morris AH.
    Am J Ophthalmol; 2002 Jan; 133(1):149-51. PubMed ID: 11755857
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R, Soliman W, Lund-Andersen H, Larsen M.
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia.
    Konstantinidis L, Mantel I, Zografos L, Ambresin A.
    Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1567-9. PubMed ID: 19727795
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration.
    Jonas JB, Harder B, Spandau UH, Kamppeter BA, Libondi T, Sauder G.
    Eur J Ophthalmol; 2006 Nov; 16(5):774-5. PubMed ID: 17061237
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
    Spandau UH, Jonas JB.
    Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.